Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multicentre, controlled Phase IIb study of Allogeneic osteoblastic cell (ALLOB) for the treatment of difficult fractures.

Trial Profile

A multicentre, controlled Phase IIb study of Allogeneic osteoblastic cell (ALLOB) for the treatment of difficult fractures.

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 06 Nov 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Allogeneic osteoblastic cell therapy Bone Therapeutics (Primary)
  • Indications Fracture
  • Focus Therapeutic Use
  • Most Recent Events

    • 06 Nov 2019 According to a Bone Therapeutics media release, the company has obtained scientific advice from European regulatory authorities to support the submission of the clinical trial application for the conduct of the trial. The first clinical batches of ALLOB are now being produced and stored as a cryopreserved stock to be used in the trial.
    • 14 Sep 2018 According to a Bone Therapeutics media release, the company expects to submit the Clinical Trial Application (CTA) for the trial in second half of 2019.
    • 24 Jan 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top